MedPath
Found 1 clinical trials|View Analysis
Sort by:

Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)

Phase 3
Active, not recruiting
Conditions
Neovascular (Wet) AMD
Interventions
Drug: Eylea® (Aflibercept)
Drug: AVT06 (proposed aflibercept biosimilar)
First Posted Date
2021-12-13
Last Posted Date
2024-05-28
Lead Sponsor
Alvotech Swiss AG
Target Recruit Count
413
Registration Number
NCT05155293
Locations
🇨🇿

Nemocnicni lekarna Sokolov, Sokolov, Czechia

🇬🇪

JSC Evex Medical Corporation, Tbilisi, Georgia

🇱🇻

Pauls Stradins Clinical University Hospital SLLC, Riga, Latvia

and more 3 locations
© Copyright 2025. All Rights Reserved by MedPath